Compare Nucor Corporation (NUE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Nucor Corporation trades at $257.14 (market cap $57.58B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Nucor Corporation is far larger — about 11.8× Travere Therapeutics Inc. Common Stock's market cap, and Nucor Corporation pays a 0.88% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NUE | TVTX | |
|---|---|---|
Market Cap | $57.58B | $4.88B |
Volume | 874,073 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $67.52 |
52-Week Low | $131.78 | $26.79 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $61.99B | $5.01B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $257.11, up 2.1% today, showing strong momentum with a 50% gain over six months. The stock is in a bullish technical trend, supported by recent earnings beats in Q1 and Q2 2026. Fundamentals reflect solid profitability with a 7.99% net margin and 13.52% ROE, though revenue has moderated from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% and recently declared its 214th consecutive dividend.
Outlook remains positive with analyst consensus at 'Buy' and a $266.88 price target, though near-term risks include competitive pressures from new steel capacity and volatility in steel prices. Earnings growth and operational efficiency are key catalysts, but investors should monitor Q3 2026 results against expectations of $5.80 EPS.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
